Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 6Completed 3Unknown 1Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 220Urinary Bladder Neoplasms 54Carcinoma, Renal Cell 52Neoplasms 27Non-Muscle Invasive Bladder Neoplasms 26Kidney Neoplasms 25Breast Neoplasms 17Carcinoma, Transitional Cell 16Adenocarcinoma 15Melanoma 11Disease 11Neoplasm Metastasis 10Colorectal Neoplasms 10Uterine Cervical Neoplasms 9Endometrial Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Ovarian Neoplasms 7Lung Neoplasms 7Triple Negative Breast Neoplasms 6Testicular Neoplasms 6Recurrence 6Clear-cell metastatic renal cell carcinoma 6Urologic Neoplasms 5Urinary Incontinence 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Carcinoma, Hepatocellular 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Urogenital Diseases × Genitourinary × Clear all
NCT07457164 2026-03-12

A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer

Antev Ltd.

Phase 2 Not yet recruiting
40 enrolled
Genitourinary

Urogenital Diseases, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡